Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Palo Alto Networks Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Palo Alto Networks Inc trades at $418.78 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 26.4× Halozyme Therapeutics Inc. Common Stock's market cap, and Palo Alto Networks Inc is more actively traded (3,886,927 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Palo Alto Networks Inc for 82 Days on average.
| HALO | PANW | |
|---|---|---|
Market Cap | $12.58B | $331.76B |
Volume | 2,179,278 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $115.22 | $419.91 |
52-Week Low | $61.63 | $141.67 |
Typical Hold Time | 1 Days | 82 Days |
Enterprise Value | $14.49B | $331.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Palo Alto Networks (PANW) trades at $418.78, up 3.3% with strong technical momentum near 52-week highs. The stock shows bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth remains robust at $9.22B for 2025, though valuation metrics appear elevated with P/E at 1,013.93 and P/S at 26.99. The company's platformization strategy and AI security services are driving investor optimism.
Outlook remains positive with 72% analyst buy ratings and $398.70 consensus target, though premium valuation and rising costs present risks. AI cybersecurity demand creates growth opportunities, but execution on large customer deals and margin sustainability will be critical for continued upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
